145 related articles for article (PubMed ID: 20596637)
1. A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.
Wan YW; Qian Y; Rathnagiriswaran S; Castranova V; Guo NL
Oncol Rep; 2010 Aug; 24(2):489-94. PubMed ID: 20596637
[TBL] [Abstract][Full Text] [Related]
2. A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types.
Mettu RK; Wan YW; Habermann JK; Ried T; Guo NL
Int J Biol Markers; 2010; 25(4):219-28. PubMed ID: 21161944
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
Tabchy A; Valero V; Vidaurre T; Lluch A; Gomez H; Martin M; Qi Y; Barajas-Figueroa LJ; Souchon E; Coutant C; Doimi FD; Ibrahim NK; Gong Y; Hortobagyi GN; Hess KR; Symmans WF; Pusztai L
Clin Cancer Res; 2010 Nov; 16(21):5351-61. PubMed ID: 20829329
[TBL] [Abstract][Full Text] [Related]
4. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
5. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer.
Lee JK; Coutant C; Kim YC; Qi Y; Theodorescu D; Symmans WF; Baggerly K; Rouzier R; Pusztai L
Clin Cancer Res; 2010 Jan; 16(2):711-8. PubMed ID: 20068086
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy.
Specht K; Harbeck N; Smida J; Annecke K; Reich U; Naehrig J; Langer R; Mages J; Busch R; Kruse E; Klein-Hitpass L; Schmitt M; Kiechle M; Hoefler H
Breast Cancer Res Treat; 2009 Nov; 118(1):45-56. PubMed ID: 18925433
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Loi S; Sirtaine N; Piette F; Salgado R; Viale G; Van Eenoo F; Rouas G; Francis P; Crown JP; Hitre E; de Azambuja E; Quinaux E; Di Leo A; Michiels S; Piccart MJ; Sotiriou C
J Clin Oncol; 2013 Mar; 31(7):860-7. PubMed ID: 23341518
[TBL] [Abstract][Full Text] [Related]
8. A population-based gene signature is predictive of breast cancer survival and chemoresponse.
Rathnagiriswaran S; Wan YW; Abraham J; Castranova V; Qian Y; Guo NL
Int J Oncol; 2010 Mar; 36(3):607-16. PubMed ID: 20126981
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer--a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group. Danish Breast Cancer Cooperative Group (DBCG).
Andersson M; Madsen EL; Overgaard M; Rose C; Dombernowsky P; Mouridsen HT
Eur J Cancer; 1999 Jan; 35(1):39-46. PubMed ID: 10211086
[TBL] [Abstract][Full Text] [Related]
10. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Fisher B; Brown AM; Dimitrov NV; Poisson R; Redmond C; Margolese RG; Bowman D; Wolmark N; Wickerham DL; Kardinal CG
J Clin Oncol; 1990 Sep; 8(9):1483-96. PubMed ID: 2202791
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R; Hausmaninger H; Haider K; Kubista E; Samonigg H; Gnant M; Manfreda D; Tschurtschenthaler G; Kolb R; Stierer M; Fridrik M; Mlineritsch B; Steindorfer P; Mittlböck M; Steger G
J Clin Oncol; 1999 Jun; 17(6):1701-9. PubMed ID: 10561206
[TBL] [Abstract][Full Text] [Related]
12. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression.
Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G
Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support.
Quintela-Fandino M; López JM; Hitt R; Gamarra S; Jimeno A; Ayala R; Hornedo J; Guzman C; Gilsanz F; Cortés-Funes H
J Clin Oncol; 2006 Aug; 24(22):3611-8. PubMed ID: 16877728
[TBL] [Abstract][Full Text] [Related]
17. In the interest of full disclosure.
Burkard ME; Tevaarwerk AJ; Wisinski KB
Lancet Oncol; 2010 Apr; 11(4):314-5; author reply 315. PubMed ID: 20359661
[No Abstract] [Full Text] [Related]
18. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
[TBL] [Abstract][Full Text] [Related]
19. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast.
Son BH; Ahn SH; Ko CD; Ka IW; Gong GY; Kim JC
Breast J; 2004; 10(1):20-6. PubMed ID: 14717755
[TBL] [Abstract][Full Text] [Related]
20. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.
Ménard S; Valagussa P; Pilotti S; Gianni L; Biganzoli E; Boracchi P; Tomasic G; Casalini P; Marubini E; Colnaghi MI; Cascinelli N; Bonadonna G
J Clin Oncol; 2001 Jan; 19(2):329-35. PubMed ID: 11208823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
